Why did Quest Diagnostics (DGX) stock move recently?

On 7/23/2026, Quest Diagnostics moved +8.6% — Quest Diagnostics surged after reporting strong Q2 2026 results that beat estimates on revenue and EPS while raising full-year 2026 revenue and EPS guidance. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Quest Diagnostics (DGX) overvalued or fairly valued?

MarketChacha shows Quest Diagnostics's valuation in context — a trailing P/E of about 24.4, a forward P/E of about 19.7, a price-to-book of about 3.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Quest Diagnostics's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.65×) from reported figures — education, not a rating.

What is Quest Diagnostics's revenue?

Quest Diagnostics reported revenue of $11.0B for FY2025, with net profit of $992.0M, per official filings.

What is the share price of Quest Diagnostics (DGX)?

Quest Diagnostics last traded at $237.14 (-0.9% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Quest Diagnostics

DGX · NYSE · Healthcare · United States

Snapshot

TickerDGX

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees46,000

HeadquartersSecaucus, United States

Websitewww.questdiagnostics.com

Filings tracked13

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Who owns it

Insiders0.4%
Institutions99.0%
Public & other0.6%

1,524 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.40%
Vanguard Capital Management LLC6.55%
Vanguard Portfolio Management LLC5.55%
State Street Corporation5.00%
Price (T.Rowe) Associates Inc4.93%
Boston Partners4.30%
JPMORGAN CHASE & CO3.19%
Geode Capital Management, LLC2.84%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.65×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend9.2% → 9.0%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 9% · PAT 8%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.0B · EPS 2.68

Est. earnings growth +10.7%

Next fiscal year

Rev $12.6B · EPS 12.06

Est. earnings growth +7.7%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$11.0B

Net margin

9.0%

ROE

13.8%

Revenue CAGR (2y)

+9.2%

Profit CAGR (2y)

+7.8%

EPS (FY2025)

8.75

Net profit (FY2025)

$992.0M

Ask MarketChacha about DGX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
Quest Diagnostics surged after reporting strong Q2 2026 results that beat estimates on revenue and EPS while raising full-year 2026 revenue and EPS guidance.
source 1 ↗source 2 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$11.0B	$992.0M	8.75	9.0%	13.8%
FY2024	$9.9B	$871.0M	7.69	8.8%	12.9%
FY2023	$9.3B	$854.0M	7.49	9.2%	13.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$3.0B	$320.0M	2.84	10.5%
2026Q1	$2.9B	$252.0M	2.24	8.7%
2025Q3	$2.8B	$245.0M	2.16	8.7%
2025Q2	$2.8B	$282.0M	2.47	10.2%
2025Q1	$2.7B	$220.0M	1.94	8.3%
2024Q3	$2.5B	$226.0M	1.99	9.1%
2024Q2	$2.4B	$229.0M	2.03	9.6%
2024Q1	$2.4B	$194.0M	1.72	8.2%
2023Q3	$2.3B	$225.0M	1.96	9.8%
2023Q2	$2.3B	$235.0M	2.05	10.1%
2023Q1	$2.3B	$202.0M	1.78	8.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/23/2026
8-K — Results of operations, Exhibits
SEC7/23/2026material
8-K — Shareholder vote results
SEC5/21/2026material
8-K — Material agreement, Exhibits
SEC5/8/2026material
8-K — Other events, Exhibits
SEC5/1/2026material
10-Q filing
SEC4/22/2026
8-K — Results of operations, Exhibits
SEC4/21/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/12/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Other events, Exhibits
SEC2/10/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

10-Q filing
SEC10/21/2025
8-K — Results of operations, Exhibits
SEC10/21/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.